Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product


  • Regulatory status:RUO
  • Type:Competitive ELISA
  • Other names:COMP, Thrombospondin-5, TSP5
  • Species:Bovine, Mouse, Pig, Rat, Goat, Sheep
Please select your region to see available products and prices.
Cat. No. Size Price

New AN-14-2004-86 96 wells (1 kit)
PubMed Product Details
Technical Data


Competitive ELISA



Sample Requirements

50 μL (pre-diluted 1/10)


Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.055 - 0.9 U/L

Limit of Detection

<0.02 U/L



  • Regulation: For research use only!
  • Assay format is 96 wells
  • Measures COMP in serum of Rat, Mouse, Sheep, Bovine, Pig, Goat
  • Animal Models of Rheumatoid Arthritis and Osteoarthritis.
  • Useful for dynamic monitoring of cartilage in multiple species.

Research topic

Bone and cartilage metabolism, Animal studies


Cartilage oligomeric matrix protein (COMP), also designated thrombospondin 5 (TSP 5), is non-collagenous glycoprotein and is a member of the thrombospondin family of extracellular proteins. COMP is a calcium-binding protein of high molecular weight (>500kDa) present in the extracellular matrix of articular, nasal and tracheal cartilage. COMP is not only cartilage-derived but was found widely in other tissues, including synovium and tendon. Intact COMP is pentameric, with five identical subunits and the carboxy-terminal globular domain of native COMP binds to collagens I, II, and IX. It has been proposed that COMP molecules are important for maintaining the properties and integrity of collagen network. In addition COMP may have a storage and delivery function for hydrophobic cellsignaling molecules such as vitamin D. The significance of COMP for normal development and function of cartilage has been underscored by the discovery that mutations of the COMP gene result in pseudoachondro¬plasia and some forms of multiple epiphyseal dysplasia. Most published studies have shown that serum levels of COMP provide important information about metabolic changes occurring in the cartilage matrix in joint disease. These studies describe that serum COMP level correlated with cartilage degradation and is a potential prognostic marker in inflammatory joint diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA). Results have demonstrated an association of increasing serum COMP levels with progressive destruction of articular cartilage monitored radiographically. OA and RA are a common disease causing pain and disability in a significant proportion of the adult population and early diagnostics of these diseases is very important for future therapy.

Product References (15)


  • Andersson A, Bernardi AI, Stubelius A, Nurkkala-Karlsson M, Ohlsson C,Carlsten H, Islander U. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised micewith collagen-induced arthritis. Rheumatology (Oxford). 2016 Mar;55(3):553-63.doi: 10.1093/rheumatology/kev355. Epub 2015 Sep 30. PubMed PMID: 26424839; PubMedCentral PMCID: PMC4746431. See more on PubMed
  • Gjertsson I, Lagerquist MK, Kristiansson E, Carlsten H, Lindholm C. Estradiol ameliorates arthritis and protects against systemic bone loss in Staphylococcusaureus infection in mice. Arthritis Res Ther. 2012 Apr 16;14(2):R76. doi:10.1186/ar3799. PubMed PMID: 22507741; PubMed Central PMCID: PMC3446450. See more on PubMed
  • Grahnemo L, Andersson A, Nurkkala-Karlsson M, Stubelius A, Lagerquist MK,Svensson MN, Ohlsson C, Carlsten H, Islander U. Trabecular bone loss in collagen antibody-induced arthritis. Arthritis Res Ther. 2015 Jul 25;17:189. doi:10.1186/s13075-015-0703-5. PubMed PMID: 26209517; PubMed Central PMCID:PMC4514982. See more on PubMed
  • Islander U, Jochems C, Stubelius A, Andersson A, Lagerquist MK, Ohlsson C,Carlsten H. Combined treatment with dexamethasone and raloxifene totallyabrogates osteoporosis and joint destruction in experimental postmenopausalarthritis. Arthritis Res Ther. 2011 Jun 20;13(3):R96. doi: 10.1186/ar3371. PubMedPMID: 21689408; PubMed Central PMCID: PMC3218911. See more on PubMed
  • Jochems C, Islander U, Erlandsson M, Verdrengh M, Ohlsson C, Carlsten H.Osteoporosis in experimental postmenopausal polyarthritis: the relativecontributions of estrogen deficiency and inflammation. Arthritis Res Ther.2005;7(4):R837-43. Epub 2005 Apr 27. PubMed PMID: 15987485; PubMed Central PMCID:PMC1175035. See more on PubMed
  • Jochems C, Islander U, Erlandsson M, Engdahl C, Lagerquist M, Gjertsson I,Ohlsson C, Holmdahl R, Carlsten H. Role of endogenous and exogenous female sexhormones in arthritis and osteoporosis development in B10.Q-ncf1*/* mice withcollagen-induced chronic arthritis. BMC Musculoskelet Disord. 2010 Dec 16;11:284.doi: 10.1186/1471-2474-11-284. PubMed PMID: 21159208; PubMed Central PMCID:PMC3009959. See more on PubMed
  • Jochems C, Islander U, Erlandsson M, Engdahl C, Lagerquist M, Ohlsson C,Nandakumar KS, Holmdahl R, Carlsten H. Effects of oestradiol and raloxifene onthe induction and effector phases of experimental postmenopausal arthritis andsecondary osteoporosis. Clin Exp Immunol. 2011 Jul;165(1):121-9. doi:10.1111/j.1365-2249.2011.04397.x. Epub 2011 Apr 19. PubMed PMID: 21501150; PubMedCentral PMCID: PMC3110328. See more on PubMed
  • Jochems C, Lagerquist M, Håkansson C, Ohlsson C, Carlsten H. Long-termanti-arthritic and anti-osteoporotic effects of raloxifene in establishedexperimental postmenopausal polyarthritis. Clin Exp Immunol. 2008Jun;152(3):593-7. doi: 10.1111/j.1365-2249.2008.03660.x. Epub 2008 Apr 24. PubMedPMID: 18435803; PubMed Central PMCID: PMC2453214. See more on PubMed
  • Kaneko K, Williams RO, Dransfield DT, Nixon AE, Sandison A, Itoh Y. Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression ofExperimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor Blockade.Arthritis Rheumatol. 2016 Feb;68(2):521-31. doi: 10.1002/art.39414. PubMed PMID: 26315469; PubMed Central PMCID: PMC4738413. See more on PubMed
  • Kawasaki K, Fushimi T, Nakamura J, Ota N. Guava leaf extract suppressesosteoarthritis progression in a rat anterior cruciate ligament transection model.Food Sci Nutr. 2018 Mar 10;6(4):800-805. doi: 10.1002/fsn3.601. eCollection 2018 Jun. PubMed PMID: 29983942; PubMed Central PMCID: PMC6021720. See more on PubMed
  • Lewis JS, Hembree WC, Furman BD, Tippets L, Cattel D, Huebner JL, Little D,DeFrate LE, Kraus VB, Guilak F, Olson SA. Acute joint pathology and synovialinflammation is associated with increased intra-articular fracture severity inthe mouse knee. Osteoarthritis Cartilage. 2011 Jul;19(7):864-73. doi:10.1016/j.joca.2011.04.011. Epub 2011 May 12. PubMed PMID: 21619936; PubMedCentral PMCID: PMC3312469. See more on PubMed
  • Pasi S, Kant R, Surolia A. Toll/Interleukin-1 Receptor Domain Derived fromTcpC (TIR-TcpC) Ameliorates Experimental Autoimmune Arthritis by Down-modulating Th17 Cell Response. J Biol Chem. 2016 Jun 3;291(23):12358-69. doi:10.1074/jbc.M116.722801. Epub 2016 Mar 28. PubMed PMID: 27022030; PubMed Central PMCID: PMC4933282. See more on PubMed
  • Seeuws S, Jacques P, Van Praet J, Drennan M, Coudenys J, Decruy T, Deschepper E, Lepescheux L, Pujuguet P, Oste L, Vandeghinste N, Brys R, Verbruggen G,Elewaut D. A multiparameter approach to monitor disease activity incollagen-induced arthritis. Arthritis Res Ther. 2010;12(4):R160. doi:10.1186/ar3119. Epub 2010 Aug 23. PubMed PMID: 20731827; PubMed Central PMCID:PMC2945063. See more on PubMed
  • Tsuji F, Yoshimi M, Katsuta O, Takai M, Ishihara K, Aono H. Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augmentscollagen-induced arthritis in DBA/1J mice. BMC Musculoskelet Disord. 2009 Feb19;10:23. doi: 10.1186/1471-2474-10-23. PubMed PMID: 19228423; PubMed CentralPMCID: PMC2652421. See more on PubMed
  • Zabeau L, Jensen CJ, Seeuws S, Venken K, Verhee A, Catteeuw D, van Loo G, ChenH, Walder K, Hollis J, Foote S, Morris MJ, Van der Heyden J, Peelman F, Oldfield BJ, Rubio JP, Elewaut D, Tavernier J. Leptin's metabolic and immune functions canbe uncoupled at the ligand/receptor interaction level. Cell Mol Life Sci. 2015Feb;72(3):629-644. doi: 10.1007/s00018-014-1697-x. Epub 2014 Aug 7. PubMed PMID: 25098352; PubMed Central PMCID: PMC4293488. See more on PubMed
Summary References (9)

References to Cartilage Oligomeric Matrix Protein

  • Bruyere O, Collette JH, Ethgen O, Rovati LC, Giacovelli G, Henrotin YE, Seidel L, Reginster JY. Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. J Rheumatol. 2003 May;30 (5):1043-50
  • Dragomir AD, Kraus VB, Renner JB, Luta G, Clark A, Vilim V, Hochberg MC, Helmick CG, Jordan JM. Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Cartilage. 2002 Sep;10 (9):687-91
  • Jordan JM, Luta G, Stabler T, Renner JB, Dragomir AD, Vilim V, Hochberg MC, Helmick CG, Kraus VB. Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. Arthritis Rheum. 2003 Mar;48 (3):675-81
  • Misumi K, Vilim V, Clegg PD, Thompson CC, Carter SD. Measurement of cartilage oligomeric matrix protein (COMP) in normal and diseased equine synovial fluids. Osteoarthritis Cartilage. 2001 Feb;9 (2):119-27
  • Skoumal M, Haberhauer G, Feyertag J, Kittl EM, Bauer K, Dunky A. Serum levels of cartilage oligomeric matrix protein are elevated in rheumatoid arthritis, but not in inflammatory rheumatic diseases such as psoriatic arthritis, reactive arthritis, Raynaud's syndrome, scleroderma, systemic lupus erythematosus, vasculitis and Sjogren's syndrome. Arthritis Res Ther. 2004;6 (2):73-4
  • Vilim V, Lenz ME, Vytasek R, Masuda K, Pavelka K, Kuettner KE, Thonar EJ. Characterization of monoclonal antibodies recognizing different fragments of cartilage oligomeric matrix protein in human body fluids. Arch Biochem Biophys. 1997 May 1;341 (1):8-16
  • Vilim V, Olejarova M, Machacek S, Gatterova J, Kraus VB, Pavelka K. Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage. 2002 Sep;10 (9):707-13
  • Vilim V, Voburka Z, Vytasek R, Senolt L, Tchetverikov I, Kraus VB, Pavelka K. Monoclonal antibodies to human cartilage oligomeric matrix protein: epitope mapping and characterization of sandwich ELISA. Clin Chim Acta. 2003 Feb;328 (1-2):59-69
  • Vilim V, Vytasek R, Olejarova M, Machacek S, Gatterova J, Prochazka B, Kraus VB, Pavelka K. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage. 2001 Oct;9 (7):612-8
Related Products Docs